Mitobronitol

Mitobronitol (Myelobromol; DBM) is a brominated analog of mannitol, also known as an anticancer agent that is classified as an alkylating agent. Mitobronitol has potential for myelosuppression associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia[1][2].

Product Specifications

CAS Number

[488-41-5]

Product Name Alternative

Myelobromol; DBM

UNSPSC

12352211

Hazard Statement

H302, H350

Target

DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mitobronitol.html

Purity

90.0

Solubility

10 mM in DMSO

Smiles

O[C@@H]([C@H]([C@@H]([C@@H](CBr)O)O)O)CBr

Molecular Formula

C6H12Br2O4

Molecular Weight

307.97

Precautions

H302, H350

References & Citations

[1]Silver RT, et al. A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. Cancer. 1987 Oct 1;60 (7) :1442-8. |[2]Silver RT, et al. A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. Cancer. 1987 Oct 1;60 (7) :1442-8. |[3]Szebeni J, et al. Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning. Leukemia. 1997 Oct;11 (10) :1769-74.